DilightTM (roflufocon E) Overnight Orthokeratology Contact Lens
Tianjin MasterVision Technology Co., Ltd. · Decision date Aug 5, 2026
What did the FDA approve?
FDA records P220015 as an original PMA application. The recorded decision is approval, dated Aug 5, 2026.
FDA approval order statement
Approval for DilightTM (roflufocon E) Overnight Orthokeratology Contact Lens. The lenses are indicated for use in the reduction of myopic refractive error in non-diseased eyes. The lens is indicated for overnight wear for the temporary reduction of myopia up to 4.00 diopters (manifest spherical equivalent) in eyes with astigmatism up to 1.50 diopters. The lenses may only be disinfected using a chemical disinfection system. Note: To maintain the Orthokeratology effect overnight lens wear must be continued on a prescribed schedule. Failure to do so can affect daily activities (e.g., night driving), cause visual fluctuations, and changes in intended correction.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ophthalmic
- Decision date
- Aug 5, 2026
Regulatory record facts
- Identifier
- P220015
- Regulatory pathway
- Premarket approval application
- Product code
- NUU
- Decision code
- APPR
- Decision date
- Aug 5, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lens, contact, orthokeratology, overnight.
- Product code
- NUU
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P220015 received
Application receipt date recorded by FDA.
P220015 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P220015. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code NUU
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Euclid Vision Corporation | PMA supplement | Apr 2, 2026 | FDA | |
| Euclid Vision Corporation | PMA supplement | Mar 12, 2026 | FDA | |
| Euclid Vision Corporation | PMA supplement | Mar 6, 2026 | FDA | |
| Contamac, Ltd. | PMA approval | Feb 10, 2026 | FDA | |
Boston Orthokeratology (oprifocon A)P010062/S015 | Bausch & Lomb | PMA supplement | Dec 16, 2025 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Tianjin MasterVision Technology Co., Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- # 89 Heyuan Rd., Jing-Jin Technology Valley, 1st Floor # 15 Bldg., Tianjin, 301721
Sources and methodology
- Original FDA record: P220015
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


